Introduction
Post-transplant lymphoproliferative disease (PTLD) incidence among solid organ recipients ranges from 0.56%-1.8% (1) (2) (3) , and is a frequent cause of death with functioning graft (US Renal Data System 2013 Annual Data Report). Histiocytic sarcoma (HS) is a rare hematologic neoplastic disease with only a few hundred cases reported worldwide, with a wide range of clinical presentations and manifestations described (4) (5) (6) (7) . This heterogeneity of reports unsuits analysis for a potential standard of care for either diagnosis or treatment. Herein we present a report of a case an HS in a kidney transplant recipient. To the best of authors' knowledge, this is the first report of an HS in a solid organ recipient not related to Epstein-Barr virus (EBV) infection.
Case Presentation
A 56-year-old woman with a history of chronic hepatitis C virus (HCV) infection diagnosed with chronic kidney disease (CKD) of unknown aetiology at the age of 27 years, was submitted to a deceaseddonor kidney transplant in 1984, and maintained under immunosuppression with prednisone and azathioprine. Post-transplant period was complicated with new-onset diabetes after transplantation (NODAT), and noninvasive cutaneous squamous cell carcinoma diagnosed in 2004 -surgically removed and without evidence of relapse. The remaining transplant period was unremarkable with a serum creatinine of 0.8 mg/dL in December 2011. Patient presented in 2012 to the emergency department due to fever of unknown origin. She also complained of a painless, smooth, and adherent to the deep muscle relentlessly growing mass on her right front thorax. Physical exploration was otherwise unremarkable -no other masses, palpable lymph nodes, or splenomegaly were found. Normal leucocyte count and haemoglobin levels were found, as were lactic dehydrogenase (LDH) and bilirubin levels. EBV serology was positive for IgG but negative for IgM. Both ultrasound and computerized tomography (CT) scan ( Figure 1A and B) revealed a highly vascularized heterogeneous mass (8×9 cm), with a necrotic centre. All other imaging studies -bone scintigraphy, mammography, and mammary ultrasonography - revealed only small residual nodules on the thorax, without evidence of brain, abdominal or pelvic masses. Immunophenotyping of both peripheral blood and bone marrow was unremarkable. Blood cultures were positive for methicillin-sensitive Staphylococcus aureus, successfully treated with cephazolin. Histology of the biopsied lesion revealed a malignant undifferentiated large cell neoplasm. No lymphoid tissue was identified. The immunohistochemical study was positive for vimentin, CD68, CD99, and CD4, and negative for all other tumour markers (Figure 2) , consistent with the diagnosis of HS (Table 1) . A positron emission tomography (PET) scan, later performed, revealed a large axillary mass, as well as multiple thoracic, abdominal, and pelvic nodules ( Figure 1C ). Evidence of disseminated disease precluded treatment with systemic chemotherapy. Due to failure to prevent the mass growth, thalidomide was added to etoposide after 1 month. Patient eventually died 3 months after the diagnosis.
Discussion
The cumulative incidence of PTLD has been reported to approach 1.8% (1-3), and represents 16% of all deaths from malignancy among solid organ recipients (8) . HS is a rare neoplastic disease of unknown aetiology, www.nephropathol.com Journal of Nephropathology, Vol 4, No 3, July 2015 accounting for less than 1% of all hematolymphoid neoplasms (9) . It most often affects males (59.4%), with a bimodal age distribution; a smaller peak between 0-29 years, and a larger one between 50-69 years old (9) . Clinical presentation varies from focal lesions to disseminated disease (7), but most frequently affects the gastrointestinal tract, skin, and lymph nodes. Surgical removal with adjunctive chemotherapy and/or radiotherapy may be curative for focal disease (5). For disseminated HS, different chemotherapy schemes with etoposide, thalidomide, and stem cell transplantation have been used, with variable outcomes (5-7). Nevertheless, prognosis is still limited, with most patients dying within 2 years after the diagnosis. Previously known as "true histiocytic lymphoma," HS is a diagnosis of exclusion. The classification according to the 2008 World Health Organization (WHO) requires the verification of the histiocytic lineage and the exclusion of other, poorly differentiated, large-cell malignancies. Even though, the presence of B-cell markers no longer excludes its diagnosis (10) . HS immunohistochemical profile most often expresses lysosome-associated (macrophage or histiocytic) markers, CD68 (in 100% of cases) and lysozyme (in 94% of cases) (11) . Additionally, a negative staining is expected for molecules related to B-cells, T-cells, accessory or dendritic cells, myeloid cells, epithelial cells, and melanocytes. Because of the monocytic origin of histiocytes, monoblastic leukaemia should be excluded (12) . Recently, CD163, a haemoglobin scavenger receptor, has been recognized as a new macrophage-related differentiation marker, which is more specific than the conventional histiocyte-related molecules (8) . Steroids, a cornerstone of immunosuppression in solid organ transplantation, inhibit gene induction by blocking the translocation of nuclear factor-κB (NFκB) from cytoplasm to nucleus. As a result, gene transcription and release of inflammatory cytokines is impaired (13) . Azathioprine, a purine analogue derivative of 6-mercaptopurine, is a broad myelocyte suppressant. It incorporates into cellular DNA and inhibits gene replication and the consequent T-cell activation (13) . Immunosuppression vintage was over 25 years in the presented case. To the authors' comprehension, the prolonged gene transcription inhibition due to longterm treatment with steroids enhanced the risk for mutation in the B and/or T-cells, possibly causing a differentiation into histiocytes or macrophages. Moreover, the association with azathioprine could have enhanced the risk for translational mutations and proliferation of a mutated monoclonal clone. Nevertheless, a large number of kidney transplant recipients are under an immunosuppression scheme 
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